Advanced search
Publication Cover
Journal of Blood Medicine Volume 13, 2022 - Issue
Submit an article Journal homepage
269
Views
2
CrossRef citations to date
0
Altmetric
Case Series

Apixaban Use in Patients with Protein C and S Deficiency: A Case Series and Review of Literature

Khalid Al Sulaiman1 Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia;2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia;3 King Abdullah International Medical Research Center, Biostatistics and Bioinformatics Department, Riyadh, Saudi Arabia;4 Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh/Jeddah, Saudi ArabiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5547-2043
ORCID Icon,
Faisal Alsuwayyid2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
,
Abdulrahman Alrashidi2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
,
Mohammed Alhijris2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
,
Faisal Almutairi2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
,
Fahad Alharthi2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
,
Laila Carolina Abu Esba1 Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia;2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia;3 King Abdullah International Medical Research Center, Biostatistics and Bioinformatics Department, Riyadh, Saudi Arabia
,
Ohoud Aljuhani4 Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh/Jeddah, Saudi Arabia;5 Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
&
Hisham A Badreldin1 Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia;2 College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia;3 King Abdullah International Medical Research Center, Biostatistics and Bioinformatics Department, Riyadh, Saudi Arabia
 show all
Pages 105-111 | Published online: 03 Mar 2022

References

  • Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–1173. doi:10.1016/s0140-6736(98)10266-0
  • Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4(1):15. doi:10.1186/1477-9560-4-15
  • De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87(9):3531–3544. doi:10.1182/blood.V87.9.3531.bloodjournal8793531
  • Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. doi:10.1182/bloodadvances.2020001830
  • Lipe B, Ornstein DL. Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation. 2011;124(14):e365–e368. doi:10.1161/CIRCULATIONAHA.111.044412
  • Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi:10.1056/NEJMoa1915103
  • Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415. doi:10.1056/NEJMoa1306638
  • Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598
  • Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62(5):509–511. doi:10.1111/j.1365-2125.2006.02806.x
  • Al Mukdad M, Al-Badriyeh D, Elewa HF. Cost-effectiveness evaluations among the direct oral anticoagulants for the prevention and treatment of venous thromboembolism: systematic review. Clin Appl Thromb. 2019;25:1076029619849103. doi:10.1177/1076029619849103
  • Keita I, Aubin-Auger I, Lalanne C, et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence. 2017;11:1625–1634. doi:10.2147/PPA.S131157
  • Burn J, Pirmohamed M. Direct oral anticoagulants versus warfarin: is new always better than the old? Open Hear. 2018;5(1):e000712. doi:10.1136/openhrt-2017-000712
  • Skelley JW, White CW, Thomason AR. The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis. 2017;43(1):24–30. doi:10.1007/s11239-016-1428-2
  • Serrao A, Lucani B, Mansour D, et al. Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterr J Hematol Infect Dis. 2019;11(1):e2019044. doi:10.4084/MJHID.2019.044
  • Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost. 2019;17(4):645–656. doi:10.1111/jth.14398
  • Zuk J, Papuga-Szela E, Zareba L, Undas A. Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. Int J Hematol. 2021;113(2):190–198. doi:10.1007/s12185-020-03012-7

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.